A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
Completed · Phase 3
Conditions studied: Keratosis, Actinic
In brief
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\^2 on the face or balding scalp.
Key facts
- Study ID
- NCT05279131
- Run by
- Almirall, S.A.
- People needed
- 105
- Starts
- 2022-06-28
- Expected to finish
- 2022-12-28
- Last updated by the study team
- 2024-01-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Having a treatment field (TF) on the face or balding scalp (excluding lips, eyelids, and inside nostrils and ears) that measures approximately 100 cm\^2 (eg, mid face) and contains 4 to 12 clinically typical, visible, and discrete actinic keratosis (AK) lesions within the TF
- Willing to avoid excessive sunlight or ultraviolet (UV) light exposure, including the use of tanning beds, to the face or scalp during the study
- Ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and provided written informed consent in accordance with institutional and regulatory guidelines
You may not qualify if…
- Presence in the TF of
- Clinically atypical and/or rapidly changing AK lesions in the TF
- Hyperkeratotic or hypertrophic lesions, recalcitrant disease (had cryosurgery on 2 previous occasions) and/or cutaneous horn
- Confluent AK lesions (ie, non-discrete lesions defined as per inclusion criteria)
- History of invasive squamous cell carcinoma (SCC), Bowen's disease, basal cell carcinoma (BCC), or other malignant tumors in the TF
- Any other dermatological disease that causes difficulty with examination
- Previous treatment with tirbanibulin ointment 1%.
- Anticipated need for inpatient hospitalization or inpatient surgery from Day 1 to Day 57
- Treatment with 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, or other treatments for AK within the TF or within 2 cm of the TF, within 8 weeks prior to the Screening visit
- Use of systemic retinoids (eg, isotretinoin, acitretin, bexarotene) within 6 months prior to the Screening visit
Where it is running
- Almirall Investigation Site 7 — Hot Springs, Arkansas, United States
- Almirall Investigation Site 6 — Encinitas, California, United States
- Almirall Investigation Site 3 — Sweetwater, Florida, United States
- Almirall Investigation Site 5 — Rolling Meadows, Illinois, United States
- Almirall Investigation Site 4 — Austin, Texas, United States
- Almirall Investigational Site 1 — College Station, Texas, United States
- Almirall Investigation Site 2 — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.